0
No votes yet
Article

Quality-of-Life Considerations With Taxane-Based Therapy in Metastatic Breast Cancer

Cathy Maxwell
CJON 2013, 17(1), 35-40 DOI: 10.1188/13.CJON.S1.35-40

As with many other types of chemotherapy, taxanes are associated with side effects that can affect patients' quality of life. One of the major side effects of taxane therapy is taxane-induced peripheral neuropathy (TIPN). The development of TIPN is accompanied by troublesome burning, tingling, and numbness; TIPN also can affect patient safety because of the decreased ability to perceive sensations (e.g., pain, heat). Pain and fatigue are common side effects of taxane therapy. These particular symptoms may hinder patients from working or performing daily activities, thus affecting quality of life. This case vignette provides an example of the symptoms that can accompany taxane therapy, including TIPN. The case vignette also demonstrates the long-lasting effects that TIPN can have on patients receiving taxane-based therapy, as well as the hindrance to the ability to work and perform daily activities because of numbness, pain, and fatigue. In addition, identification and management of taxane-related side effects are explored from the nursing perspective, and important aspects of patient education are discussed.

References 

Almadrones, L., & Arcot, R. (1999). Patient guide to peripheral neuropathy. <i>Oncology Nursing Forum, 26</i>, 1359-1360.

Almadrones, L., McGuire, D.B., Walczak, J.R., Florio, C.M., & Tian, C. (2004). Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A Gynecologic Oncology Group study. <i>Oncology Nursing Forum, 31</i>, 615-623.

American Medical Association. (2007). <i>The physician's role in medication reconciliation—Issues, strategies and safety principles.</i> Retrieved from <a target="_blank" href='http://www.ama-assn.org/resources/doc/cqi/med-rec-monograph.pdf'>http://...

Anastasia, P., & Hay, J.W. (2002). Chemotherapy-induced neuropathy: Results of an oncology nurse survey [Abstract 2618]. <i>Proceedings of the American Society of Clinical Oncology.</i> Retrieved from http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&c... <a target="_blank" href='http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&c...

Armstrong, T., Almadrones, L., & Gilbert, M.R. (2005). Chemotherapy-induced peripheral neuropathy. <i>Oncology Nursing Forum, 32</i>, 305-311. doi:10.1188/05.ONF.305-311

Authier, N., Gillet, J.P., Fialip, J., Eschalier, A., & Coudore, F. (2000). Description of a short-term Taxol-induced nociceptive neuropathy in rats. <i>Brain Research, 887</i>, 239-249. doi:10.1016/S0006-8993(00)02910-3

Bakitas, M.A. (2004). Background noise: The experience of chemotherapy-induced peripheral neuropathy. <i>Nursing Research, 56</i>, 323-331.

Barharmand, B.A. (2004). Novel challenges affecting quality of life. In B.A. Barharmand (Ed.), <i>Moving ahead—Challenges with combination therapies for colorectal cancer</i> (pp. 1-5). West Conshohocken, PA: Meniscus Educational Institute.

Bodey, G.P. (1986). Infection in cancer patients: A continuing association. <i>American Journal of Medicine, 81</i>(Suppl. 1A), 11-26.

Boehmke, M.M., & Dickerson, S.S. (2005). Symptom, symptom experiences, and symptom distress encountered by women with breast cancer undergoing current treatment modalities. <i>Cancer Nursing, 28</i>, 382-389.

Bristol-Myers Squibb. (2011). <i>Taxol® (paclitaxel)</i> [Prescribing information]. Retrieved from <a target="_blank" href='http://packageinserts.bms.com/pi/pi_taxol.pdf'>http://packageinserts.bms...

Celgene Corporation. (2012). <i>Abraxane® (nab-paclitaxel)</i> [Prescribing information]. Retrieved from <a target="_blank" href='http://www.abraxane.com/hcp/download/Abraxane_Prescribing_Information.pd...

Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I., … Glaspy, J. (1991). Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. <i>New England Journal of Medicine, 325</i>, 164-170.

Donovan, D. (2009). Management of peripheral neuropathy caused by microtubule inhibitors. <i>Clinical Journal of Oncology Nursing, 13</i>, 686-694. doi:10.1188/09.CJON.686-694

Eli Lilly and Company. (2012). <i>Cymbalta® (duloxetine)</i> [Prescribing information]. Retrieved from <a target="_blank" href='http://pi.lilly.com/us/cymbalta-pi.pdf'>http://pi.lilly.com/us/cymbalta-...

Friese, C.R. (2006). Chemotherapy-induced neutropenia: Important new data to guide nursing assessment and management. <i>Advanced Studies in Nursing, 4</i>, 21-25.

Gradishar, W.J., Krasnojon, D., Cheporov, S.V., Makhson, A.N., Manikhas, G.M., Clawson, A., & Iglesias, J. (2012). Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: Final analysis of overall survival. <i>Clinical Breast Cancer, 12</i>, 313-321. doi:10.1016/j.clbc.2012.05.001

Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., … O'Shaughnessy, J. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. <i>Journal of Clinical Oncology, 23</i>, 7794-7803. doi:10.1200/JCO .2005.04.937

Green, M.D., Koelbl, H., Baselga, J., Galid, A., Guillem, V., Gascon, P., … Piccart, M.J. (2003). A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. <i>Annals of Oncology, 14</i>, 29-35. doi:10.1093/annonc/mdg019

Harris, K.A. (1998). The informational needs of patients with cancer and their families. <i>Cancer Practice, 6</i>, 39-46.

Hershman, D.L., Weimer, L.H., Wang, A., Kranwinkel, G., Brafman, L., Fuentes, D., … Crew, K.D. (2011). Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. <i>Breast Cancer Research and Treatment, 125</i>, 767-774. doi:10.1007/s10549-010-1278-0

Kobayashi, N., & Mundel, P. (1998). A role of microtubules during the formation of cell processes in neuronal and non-neuronal cells. <i>Cell Tissue Research, 291</i>, 163-174.

Makino, H. (2004). Treatment and care of neurotoxicity from taxane anticancer agents. <i>Breast Cancer, 11</i>, 100-104.

Markman, M. (2006). Chemotherapy-induced peripheral neuropathy: Underreported and underappreciated. <i>Current Pain and Headache Reports, 10</i>, 275-278.

Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., & Carbone, P.P. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. <i>American Journal of Clinical Oncology, 5</i>, 649-655.

Pachman, D.R., Barton, D.L., Watson, J.C., & Loprinzi, C.L. (2011). Chemotherapy-induced peripheral neuropathy: Prevention and treatment. <i>Clinical Pharmacology and Therapeutics, 90</i>, 377-387. doi:10.1038/clpt.2011.115

Paice, J.A. (2007). Peripheral neuropathy: Experimental findings, clinical approaches. <i>Journal of Supportive Oncology, 5</i>, 61-63.

Pfizer Inc. (2012). <i>Neurontin® (gabapentin)</i> [Prescribing information]. Retrieved from <a target="_blank" href='http://www.pfizer.com/products/rx/rx_product_neurontin.jsp'>http://www.p...

Polomano, R.C., & Farrar, J.T. (2006). Pain and neuropathy in cancer survivors. <i>American Journal of Nursing, 106</i>(Suppl. 3), 39-47.

Reyes-Gibby, C.C., McCrory, L.L., & Cleeland, C.S. (2003). Variations in patients' self-report of pain by treatment setting. <i>Journal of Pain and Symptom Management, 25</i>, 444-448.

sanofi-aventis. (2010). <i>Taxotere® (docetaxel)</i> [Prescribing information]. Retrieved from <a target="_blank" href='http://products.sanofi.us/Taxotere/taxotere.html'>http://products.sanofi...

Scripture, C.D., Figg, W.D., & Sparreboom, A. (2006). Peripheral neuropathy induced by paclitaxel: Recent insights and future perspectives. <i>Current Neuropharmacology, 4</i>, 165-172.

Smith, E.M., Pang, H., Cirrincione, C., Fleishman, S. B., Paskett, E. D., Fadul, C.E., … Gilman, P. (2012). CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN) [Abstract CRA9013]. <i>Journal of Clinical Oncology.</i> Retrieved from http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&c... <a target="_blank" href='http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&c...

Szpiro, K.A., Harrison, M.B., Van Den Kerkhof, E.G., & Lougheed, M.D. (2008). Patient education in the emergency department: A systematic review of interventions and outcomes. <i>Advanced Emergency Nursing Journal, 30</i>, 34-39.

Tofthagen, C. (2010). Patient perceptions associated with chemotherapy-induced peripheral neuropathy [Online exclusive]. <i>Clinical Journal of Oncology Nursing, 14</i>, E22-E28. doi:10.1188/10.CJON.E22-E28

Visovsky, C., Collins, M., Abbott, L., Aschenbrenner, J., & Hart, C. (2007). Putting Evidence Into Practice: Evidence-based interventions for chemotherapy-induced peripheral neuropathy. <i>Clinical Journal of Oncology Nursing, 11</i>, 901-913. doi:10.1188/07.CJON.901-913

Wickham, R. (2007). Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. <i>Clinical Journal of Oncology Nursing, 11</i>, 361-376. doi:10.1188/07.CJON.361-376

Windebank, A.J., Blexrud, M.D., & de Groen, P.C. (1994). Potential neurotoxicity of the solvent vehicle for cyclosporine. <i>Journal of Pharmacology and Experimental Therapeutics, 268</i>, 1051-1056.

Wolf, S., Barton, D., Kottschade, L., Grothey, A., & Loprinzi, C. (2008). Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. <i>European Journal of Cancer, 44</i>, 1507-1515. doi:10.1016/j.ejca.2008.04.018